Roth Capital is cutting its price target on Galena Biopharma (Nasdaq: GALE) from $12 down to $7, but maintains a ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE